CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Genmab A/S

GMAB
$21.44BLarge Cap

Next catalyst

Phase 2March 2027

Epcoritamab

Diffuse Large B-Cell Lymphoma

Get an email about GMAB's next catalysts

Track Genmab A/S (GMAB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 10 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline

Catalyst Timeline

11 upcoming, 1 past

Phase 2Next

Epcoritamab Phase 2 Est. Readout

March 2027~Epcoritamab184

Primary completion for Epcoritamab trial (NCT05451810) in Diffuse Large B-Cell Lymphoma

Source
Phase 2

Epcoritamab Phase 2 Est. Readout

April 2027~Epcoritamab20

Estimated primary completion for Epcoritamab trial (NCT06510491) in Waldenstrom Macroglobulinemia. Topline data typically follows completion by weeks to months.

Source
Phase 2

Epcoritamab Phase 2 Est. Readout

May 2027~Epcoritamab35

Estimated primary completion for Epcoritamab trial (NCT06510361) in Lymphoma. Topline data typically follows completion by weeks to months.

Source
Phase 3

Vincristine Phase 3 Est. Readout (EPCORE DLBCL-2)

June 2027~Vincristine900

Estimated primary completion for Vincristine trial (NCT05578976) in Diffuse Large B-Cell Lymphoma. Topline data typically follows completion by weeks to months.

Source
Phase 2

Epcoritamab Phase 2 Est. Readout

Q3 2027~QEpcoritamab22

Estimated primary completion for Epcoritamab trial (NCT07108998) in CLL/SLL. Topline data typically follows completion by weeks to months.

Source
Phase 3

Acasunlimab Phase 3 Est. Readout

Q3 2027~QAcasunlimab191

Estimated primary completion for Acasunlimab trial (NCT06635824) in PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC. Topline data typically follows completion by weeks to months.

Source
Phase 2

Epcoritamab Phase 2 Est. Readout

Q3 2027~QEpcoritamab38

Estimated primary completion for Epcoritamab trial (NCT06536049) in Recurrent Diffuse Large B-Cell Lymphoma. Topline data typically follows completion by weeks to months.

Source
Phase 3

Rina-S Phase 3 Est. Readout (RAINFOL-02)

September 2027~Rina-S82

Estimated primary completion for Rina-S trial (NCT07604766) in Platinum-resistant Ovarian Cancer. Topline data typically follows completion by weeks to months.

Source

How GMAB's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical PreparationsBiotechnology🇺🇸Europe1253 COPENHAGEN K3.1K employees

Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab (Suzhou) Co., Ltd. in Suzhou, China. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US.

Website
Drug Pipeline

Leucovorin (Calcium Folinate)

Phase 3

Colorectal Cancer

tisotumab vedotin

Phase 3

Solid Tumor

Zalutumumab

Phase 3

Head and Neck Cancer

Epcoritamab

Phase 3

Diffuse Large B-Cell Lymphoma

Rina-S

Phase 3

Endometrial Cancer

Acasunlimab

Phase 3

Cutaneous Melanoma

Pegylated liposomal doxorubicin (PLD)

Phase 3

Platinum-resistant Ovarian Cancer

Vincristine

Phase 3

Follicular Lymphoma (FL)

vinorelbine

Phase 3

Cervical Cancer

Petosemtamab

Phase 3

Left-sided Colorectal Cancer

PLD

Phase 3

Platinum-Sensitive Ovarian Cancer

Acasunlimab in combination with docetaxel (in a single expansion cohort)

Phase 2

Solid Tumors

HuMax-CD4

Phase 2

Cutaneous T-Cell Lymphoma

Erythromycin

Phase 2

High Grade Epithelial Ovarian Cancer

SoC chemotherapy treatment 2

Phase 2

Metastatic Colorectal Cancer

Rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone

Phase 2

Relapsed Large B-cell Lymphoma

Investigation agent 2

Phase 2

Relapsed Follicular Lymphoma

CC-99282

Phase 2

Non-Hodgkin Lymphoma

Doxorubicin Hydrochloride

Phase 2

Non-Hodgkin Lymphoma

SoC chemotherapy treatment 1

Phase 2

Metastatic Colorectal Cancer

GDP

Phase 2

Large Cell Lymphoma, Diffuse

Zanubrutinib

Phase 2

Follicular Lymphoma

Loncastuximab Tesirine

Phase 2

Large B-cell Lymphoma

gemcitabine and oxaliplatin

Phase 2

Diffuse Large B-Cell Lymphoma

GEN1042

Phase 2

Malignant Solid Tumor

rituximab, ifosfamide, carboplatin, and etoposide phosphate

Phase 2

Diffuse Large B-Cell Lymphoma

Rituximab combined with cyclophosphamide, vincristine, and prednisone

Phase 2

Relapsed Large B-cell Lymphoma

Epcoritamab (maintenance)

Phase 2

Diffuse Large B Cell Lymphoma

Epcoritamab (monotherapy)

Phase 2

Diffuse Large B Cell Lymphoma

Rituximab combined with polatuzumab, cyclophosphamide, doxorubicin, and prednisone

Phase 2

Relapsed Large B-cell Lymphoma

Enapotamab vedotin (HuMax-AXL-ADC)

Phase 2

Ovarian Cancer

GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells

Phase 2

Breast Cancer, Breast Neoplasms

Investigation agent 3

Phase 2

Relapsed Follicular Lymphoma

GEN1286

Phase 2

Advanced Solid Tumor

Frequently asked questions

What is in Genmab A/S's drug pipeline?→

CatalystAlert tracks 34 drug candidates in Genmab A/S's (GMAB) pipeline across Phase 3, Phase 2. Its lead program is Epcoritamab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Genmab A/S's next FDA catalyst?→

Genmab A/S's (GMAB) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track GMAB biotech catalysts?→

Add GMAB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Genmab A/S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply